Can Moderna Repeat COVID-19 Success In Influenza Market?
First Subject Dosed In Flu Vaccine Trial
The company could have a significant competitive position thanks to the ability to rapidly develop and combine vaccines using mRNA technology.
You may also be interested in...
AstraZeneca and Moderna disclosed clinical and preclinical evidence that their COVID-19 vaccines, Vaxzevria and mRNA-1273, provide protection against the B.1.617.2 strain.
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.
After a baptism of fire during the coronavirus pandemic, mRNA vaccine technology has earned its stripes. In less than a year, mRNA vaccines have been catapulted from interesting pipeline prospects to game-changers in the fight against COVID-19. But what does this success mean for the future of the technology?